Table 1 Patient Demographics and Clinical Characteristics
From: Insight into the current practice of ototoxicity monitoring during cisplatin therapy
Characteristic | N (%) |
|---|---|
Sex | |
Male | 216 (60) |
Female | 163 (40) |
Malignancy type | |
Breast | 3 (0.8) |
Central Nervous System | 12 (3.2) |
Gastrointestinal | 32 (8.4) |
Gynecologic | 74 (19.5) |
Head & Neck | 122 (32.2) |
Hematologic | 3 (0.8) |
Lung | 51 (13.5) |
Sarcoma | 7 (1.8) |
Skin | 5 (1.3) |
Urologic | 70 (18.5) |
Treatment intent | |
Curative | 305 (80.5) |
Palliative | 65 (17.2) |
Unknown | 9 (2.3) |
History of Prior Radiation to Head and Neck | |
Yes | 16 (4.2) |
No | 312 (82.3) |
Unknown | 51 (13.5) |
Concurrent Radiation Treatment | |
Yes | 204 (53.8) |
No | 175 (46.2) |
History of Hearing Loss prior to treatment | |
Yes | 104 (27.4) |
No | 183 (48.3) |
Unknown | 92 (24.3) |